Utah

1. 1What the law is

Utah's psilocybin route runs through hospitals, and only certain ones. Utah Code 58-37-309, renumbered from 58-37-3.5 and effective in its current form 6 May 2026, lets a qualifying healthcare system include psilocybin or MDMA that is in FDA Phase 3 testing in a behavioral health treatment program. The statute defines that system three ways: a privately owned, non-profit, vertically integrated healthcare system operating at least 15 licensed hospitals in the state; a health care system closely affiliated with an institution of higher education listed in Section 53H-1-102; or a health care system closely affiliated with a private postsecondary educational institution as defined in Section 53H-1-101. The drug may be used only under the direct supervision and control of that system and its licensed providers, and only by adults. This is a clinical authorization, not a decriminalization, and it is not a route a patient can enter alone. The section protects only conduct that complies with it, nothing leaves the clinical setting, and possession outside it is a Schedule I offense. Whether any program is running is not established by the public record. The report that participating systems owed the Health and Human Services Interim Committee before 1 July 2026 is registered with the Legislature as report id 648 and is recorded Overdue with no submission listed, and the statute attaches that duty only to a system that creates a program. The authorization is time-limited as well: it is repealed on 1 July 2027. Two 2026 acts sit alongside it. HB 390 authorizes the Huntsman Mental Health Institute to conduct a safety and feasibility study of psychedelic-assisted therapy for veterans with treatment-resistant PTSD, naming MDMA, 5-MeO-DMT and psilocybin; the act appropriates no money itself, and the study must begin by 1 January 2027 if legislative appropriations together with gifts and donations reach an amount the institute judges sufficient. SB 83 provides that if the federal government schedules an FDA-approved pharmaceutical composition of a Schedule I substance outside Schedule I, that product is scheduled the same way in Utah automatically. No approved psilocybin medicine exists, so nothing changes under it today.

Utah occupies an unusual position in United States psychedelics law: psilocybin remains a Schedule I controlled substance, yet the state operates an enacted clinical pathway. SB 266 (2024), which took effect May 1, 2024 after Governor Cox allowed it to become law without his signature, established a hospital-based pilot permitting licensed providers at University of Utah Health and Intermountain Health to administer psilocybin and MDMA as behavioral health treatments in supervised clinical settings. The substances may not be taken home and may not be administered to minors; the pilot runs through 2027. In March 2026, Governor Cox signed HB 390, the Veterans PTSD Clinical Research Amendments, which funds a $1 million state clinical trial of psychedelic-assisted therapy for veterans with treatment-resistant PTSD at the Huntsman Mental Health Institute. The groundwork was laid in 2022, when HB 167 created the Mental Illness Psychotherapy Drug Task Force to study psilocybin and MDMA; its report recommended a cautious, clinically supervised approach. Outside these programs, possession, cultivation, and sale of psilocybin remain criminal offenses in Utah, and no decriminalization or personal-use measure is in effect.

Utah is the unexpected pilot leader among conservative states. Rather than ballot-box legalization, it routed psychedelics through its two dominant hospital systems, a mechanism with built-in institutional accountability that has proven politically durable in a legislature otherwise cautious on drug policy. The next decision points are fixed in statute: pilot providers must report outcomes to the Legislature by July 1, 2026, and the SB 266 program sunsets in 2027, so lawmakers will weigh extension, expansion, or expiry largely on the strength of that reporting. HB 390's veterans trial, with applications expected by mid-2026, adds a second data stream. The near-term trajectory is continued clinical-channel incrementalism rather than broader access.